Research

Hormonal

Use of GLP-1 receptor agonists is not associated with an increased risk of gastrointestinal cancers and may be associated with reduced risks of colorectal and liver cancers.

Current evidence from large randomized trials indicates that GLP-1 receptor agonists do not increase the risk of gastrointestinal cancers. In fact, they may be associated with a reduced risk of colorectal and liver cancers, particularly in older and obese patients. While these findings are reassuring, cancer was often a secondary endpoint, so long-term monitoring remains important.

GoodRefutesHIGH confidence
GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0.81: 95% CI: 0.68–0.96). Subgroup analyses indicated reduced risks of colorectal cancer (HR 0.81: 95% CI: 0.68–0.96) and liver cancer (HR: 0.74; 95% CI: 0.62–0.88).
Adil Farooq Wali et al. · Frontiers in Pharmacology · 2026

Why this rating

High-quality evidence from a meta-analysis of 93 RCTs with 1.85 million participants, though cancer was a secondary endpoint in most trials.

Source

Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies

Adil Farooq Wali et al. · Frontiers in Pharmacology · 2026

DOI 10.3389/fphar.2026.1736380

Meta-analysis · 93 studiesCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →